Menu Search
Equities

Sangamo Therapeutics Inc

GBY:DUS

Sangamo Therapeutics Inc

Actions
  • Price (EUR)2.74
  • Today's Change0.287 / 11.70%
  • Shares traded300.00
  • 1 Year change+669.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

  • Revenue in USD (TTM)12.28m
  • Net income in USD-249.68m
  • Incorporated1995
  • Employees405.00
  • Location
    Sangamo Therapeutics Inc501 Canal Blvd.RICHMOND 94084United StatesUSA
  • Phone+1 (510) 970-6000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.sangamo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.